Ensysce Biosciences, Inc. (NASDAQ:ENSC) shares moved downward early Thursday, because the clinical-stage biotech firm making use of transformative chemistry to enhance prescription drug security targeted on decreasing abuse and overdose, introduced the initiation of PF614-104, ‘A Randomized, Double-blind, Placebo and Lively-Managed, Crossover Examine to Consider the Oral Abuse Potential of PF614 In contrast with Oxycodone Quick-Launch Tablets, and Placebo in Non-Dependent Leisure Opioid Customers.’
The research is being carried out by Dr. Brad Vince, from Dr. Vince Medical Analysis (DVCR), at one of the crucial modern and technologically superior medical pharmacology models, newly constructed and not too long ago opened in Overland Park, Kansas. This research is designed to check and ensure that PF614 could have much less potential for drug liking versus instant launch oxycodone at equal drug dosages.
Dr. Invoice Schmidt, Chief Medical Officer of Ensysce, commented, “That is the second Human Abuse Potential (HAP) research of PF614 to be carried out this 12 months demonstrating the Firm’s speedy development within the improvement of our lead drug candidate. Such research are essential for the abuse deterrent labeling of any new opioid drug product and this research serves as an necessary step in establishing that PF614 is differentiated from present merchandise in the marketplace.
Ensysce Biosciences is a clinical-stage biotech firm utilizing its proprietary know-how platforms to develop safer pharmaceuticals. Leveraging its Trypsin Activated Abuse Safety (TAAPTM) and Multi-Tablet Abuse Resistance (MPAR) platforms, the Firm is within the means of growing a singular, tamper-proof remedy possibility for ache that minimizes the danger of each drug abuse and overdose.
ENSC shares dropped a penny, or 6.1%, to 22.3 cents.